Immuneering Corporation
IMRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $121 | $54 | $68 |
| - Cash | $228 | $26 | $36 | $36 |
| + Debt | $4 | $4 | $4 | $4 |
| Enterprise Value | – | $99 | $22 | $36 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$15 | -$15 | -$15 | -$18 |
| % Margin | – | – | – | – |
| Net Income | -$15 | -$14 | -$15 | -$18 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.38 | -0.4 | -0.42 | -0.58 |
| % Growth | 5% | 4.8% | 27.6% | – |
| Operating Cash Flow | -$12 | -$9 | -$14 | -$15 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$12 | -$9 | -$14 | -$15 |